Taming the tiger: insights into sarcoid myositis through 18F-FDG PET/MRI imaging

Myositis, characterized by inflammation of the skeletal muscles, represents a significant manifestation of sarcoidosis, a systemic granulomatous disease. While sarcoidosis traditionally affects the lungs and lymph nodes, its involvement of the musculoskeletal system, termed sarcoid myositis, presents unique diagnostic and therapeutic challenges.1 In this context, MRI and 18F-fluorodeoxyglucose (18F-FDG) PET play a pivotal role in unraveling the complexities of sarcoidosis myositis, assessing the extent and severity of the disease, its progression, and treatment response.2,3 To enhance diagnostic accuracy, the integration of anatomical and functional imaging is often achieved through “hybrid” modalities such as PET/CT and, more recently but less clinically available, PET/MRI.